MIAMI—Talent Testing Services today announced that its testing policy for syphilis, under its current basic panel, will continue to include the TrepSure EIA test. This test will be used in conjunction with RPR and will continue to be an integral part of its basic clinical panel including the molecular tests for HIV, Chlamydia and Gonorrhea.
“The TrepSure EIA test offers an additional protection of our talent population as an initial indicator for syphilis. Used in conjunction with the RPR test plus patient history, TrepSure indicates past infections and is an effective indicator of acute syphilis infection,” said Sixto Pacheco, president & CEO of TTS. “Talent Testing Service will continue to develop comprehensive test programs that not only protect the health of the talent but also address our industry’s concerns.”
TTS will continue to provide cleared status information to the APHSS database based on the existing clearance algorithm currently in place.
The company has long offered testing for HIV RNA by PCR methodology, which detects the presence of the virus earlier than all other tests.
Testing for Hepatitis B, Hepatitis C, Gonorrhea, Chlamydia, Syphilis and others is also available.
